$heff's $tation of $tocks & $olid DD

[usasingh1]

$ITCI Intra-Cellular Therapies is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. Patient enrollment in ITI-007-302, the second Phase 3 clinical trial of ITI-007 in schizophrenia, was completed in the second quarter of 2016 and the company anticipates topline data from this trial will be available later this year. Separately, the company expects to provide more details regarding its clinical development plans for its ITI-214 program, the lead compound in the phosphodiesterase platform, later this year.